NCT04514406 (APERTO CVS) is a clinical trial of APERTO OTW DCB in Dialysis; Complications, sponsored by Cardionovum GmbH.

Who is sponsoring NCT04514406?

NCT04514406 is sponsored by Cardionovum GmbH.

What drugs are being tested in NCT04514406?

Interventions in NCT04514406: APERTO OTW DCB.

What condition does NCT04514406 study?

NCT04514406 studies Dialysis; Complications, Central Vein Obstruction, Stenosis, Restenosis.

Is NCT04514406 still recruiting?

NCT04514406 is currently terminated. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT04514406: APERTO CVS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

APERTO CVS PMCF Study

Terminated Last updated 7 February 2024

What this trial tests

trial testing APERTO OTW DCB in Dialysis; Complications in 6 participants. Terminated before completion.

Timeline

25 January 2021

Primary endpoint
1 December 2023

1 December 2023

Quick facts

Lead sponsor	Cardionovum GmbH
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	6
Start date	25 January 2021
Primary completion	1 December 2023
Estimated completion	1 December 2023
Sites	2 locations across Germany

Drugs / interventions tested

APERTO OTW DCB

Conditions studied

Dialysis; Complications — all drugs for Dialysis; Complications →
Central Vein Obstruction — all drugs for Central Vein Obstruction →
Stenosis — all drugs for Stenosis →
Restenosis — all drugs for Restenosis →

Sponsor

Cardionovum GmbH — full company profile →

Who can join

18 and older, any sex, with Dialysis; Complications or Central Vein Obstruction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective Observational Single Arm study aimed to assess safety and effectiveness of APERTO OTW DCB in treating stenosis and restenosis of central veins in dialysis patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Dialysis; Complications

Currently open trials in the same condition.

NCT07412834 — Safely Disconnect From the Dialysis Machine in an Emergency Situation · active not recruiting
NCT03629977 — Timing of Renal Replacement Therapy in the Critically Ill Patients · recruiting
NCT07045155 — Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis · Phase 4 · recruiting
NCT05490225 — Access Cannulation Trial II · NA · recruiting
NCT05418647 — Effect of Low Versus High Dialysate Sodium Concentration During Hemodialysis on Dialysis Recovery Time · NA · recruiting

Other Cardionovum GmbH trials

Trials by the same sponsor.

NCT03745053 — XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04514406 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cardionovum GmbH
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04514406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing